Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis
Summary: Background: Voluntary licences are increasingly being used to expand access to patented essential medicines in low-income and middle-income countries (LMICs). Since 2014, non-exclusive voluntary licences have been issued by Gilead and Bristol-Myers Squibb for key drugs for hepatitis C virus...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Livro |
| Publicado em: |
Elsevier,
2019-09-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Número de Chamada: |
A1234.567 |
|---|---|
| Cópia 1 | Disponível |